The first report of the application of Helix pomatia lectin to sections of human breast came from Leathem et al. (1983) , in which binding was observed in normal breast epithelium and in the majority of carcinomas. This was followed by two short reports from the same group in which a relationship between Helix pomatia binding and axillary node metastasis was described (Leathem et al., 1984; 1985) . The first study had shown consistent binding to normal breast, so it was rather surprising that binding to breast cancers related to a feature which is the hallmark of malignancy. Unfortunately the nature of glycoconjugate(s) to which the lectin was binding does not seem to have been analysed further at that time, or subsequently.
The publications following these have all concentrated on the binding of Helix pomatia to breast cancers and whether or not it relates to node status and relapse free survival and overall survival. If Helix pomatia binding is to be of value as a prognostic marker it should fulfil the minimum criteria proposed by McGuire (1991) with respect to sample size, patient population bias, method validation, optimisation of cut-off values and reproducibility. Currently it does not.
Those studies which considered Helix pomatia binding to be of prognostic value have been those of Fenlon et al. (1987); Leathem and Brooks (1987); Fukutomi et al., (1989) and Brooks and Leathem (1991a) , with some differences between them. The first report from Leathem and Brooks (1987) suggested that Helix pomatia binding was only of significance in the pre-menopausal group, whereas their extended series (199la) found no association with age. Also its prognostic value was due to its relationship to node status and was not independent. Those studies which have failed to find Helix pomatia binding to be of significance have been those of Galea et al. (1991 ), Taylor et al. (1991 and Gusterson et al. (1993) which was an extension of the pilot study of Taylor et al. Noguchi et al. (1993) considered Helix pomatia staining to be of some use but to be equivalent to various clinical parameters in predicting nodal metastasis. in this current issue find it to be associated with node status but not an independent marker of prognosis. Why all the differences?
Some of the studies which differ with regard to significance of Helix pomatia binding have similar frequency of detection, while other studies which agree with regard to significance have a different frequency, e.g. Galea et al. (1991) describe 81% as staining and Brooks and Leatham (1991a) 79% whereas Fukutomi et al. (1989) and Noguchi et al. (1993) have 45% positive. Gusterson et al. (1993) fall in between at 67%. The disparities could be due to differences in patient population, methods of detection and assessment of what is 'positive'. The higher scores come from a British population, the intermediate score from a world-wide study and the low score from Japan, so patient population could be a factor. Gusterson et al. (1993) found staining on endothelium in 46% of cases, and Fukutomi et al. (1991) observed staining of red cells in blood group A patients. Although binding to blood groups A and AB may not be a factor in all cases, it could be significant in some and could account for population-based variations.
The next factor to be considered is method of detection: the use of a simple peroxidase-labelled lectin vs an indirect method involving application of an antibody to Helix pomatia and PAP or avidin-biotin immunohistochemical methods, or application of biotinylated lectin followed by an avidin-biotin system. These methods are liable to differ substantially in their sensitivity. Other variations which were employed initially by some workers included the use of trypsin to expose cryptic sites. Interestingly, removal of terminal sialic acid by neuraminidase treatment (Fenlon et al., 1987) prior to lectin binding completely changed the relationship to node status. Galea et al. (1991) used the simple direct approach, while Brooks and Leathem (1991a) used an indirect approach which would be expected to be more sensitive. Galea et al. accepted that their failure to identify a correlation between node status and prognosis could be due to the method. Brooks and Leathem (199 la) compared direct and indirect methods and found only weak correlations with the former. This seems to support the proposal that the usefulness of Helix pomatia lectin is critically limited by the sensitivity of the method. However, the recorded frequency with which binding of Helix pomatia detected by the two methods was very similar and Gusterson et al. (1993) appeared to get the same results when they compared both methods on the same set of cancers. One explanation could be that the more sensitive detection system might allow identification of a glycoprotein with a terminal N acetyl galactosamine, present at lower levels but nonetheless is critical for the claimed clinical associations. These uncertainties emphasise the need to know much more about the structure of the glycoproteins detected by Helix pomatia binding.
Optimisation of cut-off values is another factor important in the assessment of prognostic markers. Leathem and Brooks (1987) considered cases with no staining or very weak staining of occasional cells to be negative. This was extended to include cases with up to 50% of cells with weak staining (Brooks & Leathem, 1991a) . However, despite all the other differences with regard to Helix pomatia binding, all reports appear to agree that it is easy to subdivide cases into positive and negative.
Those studies which find a relationship with prognosis appear to agree that it is not independent of node status (See Thomas et al., this issue) . The principal value of Helix pomatia binding might therefore be in prediction of lymph node status. The question arises how good a prediction is required. Thus 31.6% of carcinomas with staining had no evidence of metastasis (Brooks & Leathem, 1991a) although looked at a different way only 10% of those with no staining had metastasised. It would be difficult to use Helix pomatia binding to influence the therapy, based on these figures.
The evidence that tumour cell surface oligosaccharides have a significant role in metastasis comes from studies of cell lines, predominantly of murine tumours. The degree of sialylation of subterminal galactose and N-acetylgalactosamine residues shows a good correlation with metastatic potential (Yogeeswaran & Salk, 1991; Altevogt et al., 1983) . Blockage of protein glycosylation or oligosaccharide processing results in inhibition of experimental metastasis (Humphries et al., 1986) . In theory greater knowledge of the tumour cell surface glycoproteins involved in metastasis could help in the design of drugs to inhibit their synthesis, assembly, or presentation.
The use of lectin binding to identify specific glycoproteins is fraught with problems. Although lectins bind to specific sugar groups, these can be common to several glycoproteins within the same cell or tissue. Minor variations in the composition of oligosaccharide chains, not necessarily involving the lectin-specific sugars, can affect binding. This sort of microheterogeneity is more frequent in carcinomas (Ogata et al., 1976) . Perhaps because of these problems it has not been possible to assign prognostic significance to the binding of other lectins in breast carcinoma (Walker, 1990) , and it is not surprising that conflicting results have been generated from different studies with the Helix pomatia lectin.
It is evident that while Helix pomatia lectin may be an interesting research tool to examine breast cancer-associated glycoproteins it could not be used clinically. What is required is identification and analysis of the putative metastasisrelated glycoprotein, and the subsequent generation of specific reagents to it.
